A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoid arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms AURIEL-RA
- Sponsors Merck KGaA
- 30 May 2017 Planned End Date changed from 29 Sep 2018 to 9 Aug 2018.
- 30 May 2017 Planned primary completion date changed from 29 Jun 2018 to 9 May 2018.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting.